SCHEMBL720430

SCHEMBL720430

CCC1(CC(N)=O)OCCO1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3257641 0.80 TSHR (0.33)
SCHEMBL22292128 0.78
SCHEMBL5066889 0.75 MGAM (0.38) MAPT
SCHEMBL17818836 0.75 SMN1; SMN2 (0.36) KDM4EMAPTAPOBEC3G
SCHEMBL10207770 0.74 GAA (0.41) KDM4E
SCHEMBL1018739 0.72
SCHEMBL24812030 0.71 GRIN2D (0.36)
SCHEMBL14146256 0.70 ALDH1A1 (0.38)
SCHEMBL7226727 0.69
SCHEMBL712145 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240442-B1 PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN MEDICHEM KOREA CO LTD (KR) 2012-06-20 EP disclosed
US-8124790-B2 Preparation process useful in synthesis of atorvastatin MEDICHEM KOREA CO., LTD. (KR) 2012-02-28 US disclosed
US-20110112309-A1 PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN MEDICHEM KOREA CO., LTD. (KR) 2011-05-12 US disclosed
EP-2240442-A2 PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN Medichem Korea. Co., Ltd. (KR) 2010-10-20 EP disclosed
WO-2009084773-A2 PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN MEDICHEM KOREA. CO., LTD. (KR) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112309-A1 PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN HMGCR, DHCR7, LIPA KDM4E 1306/4885MAPT 3642/4885APOBEC3G 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.